Ann M Horan

US Patent:

6569668, May 27, 2003

Filed:

Mar 29, 2001

Appl. No.:

09/821167

Inventors:

Ann C. Horan - Summit NJ

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C12N 120

US Classification:

4352523, 4353201, 536 231, 536 237

Abstract:

Plasmid genes from pMR2 have been isolated, cloned, sequenced and functionally identified. These genes have been used to create vectors which can be used to express actinomycete genes, manipulate metabolic pathways and produce useful gene products such as hybrid antibiotics.

US Patent:

6861513, Mar 1, 2005

Filed:

Jan 11, 2001

Appl. No.:

09/758759

Inventors:

Thomas J. Hosted - Summit NJ, US
Tim X. Wang - Roselle Park NJ, US
Ann C. Horan - Summit NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C07H021/04

US Classification:

536 231, 4353201, 4352523, 435471

Abstract:

This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A. site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into. Thus, the invention further provides methods for introducing heterologous genes into an actinomycete chromosome using this particular vector.

US Patent:

7220567, May 22, 2007

Filed:

May 15, 2001

Appl. No.:

09/855340

Inventors:

Ann C. Horan - Summit NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C12N 1/21
C12N 15/00
C12N 15/74
C07H 21/04

US Classification:

4352523, 4353201, 435471, 536 231, 536 237

Abstract:

Plasmid genes from var. ATCC39149 pMLP1 have been isolated cloned, sequenced and functionally identified. These genes have been used to create vectors which integrate in a site-specific manner into the host chromosome of actinomycete species.

US Patent:

7229813, Jun 12, 2007

Filed:

Dec 23, 2004

Appl. No.:

11/021825

Inventors:

Thomas J. Hosted - Summit NJ, US
Tim X. Wang - Roselle Park NJ, US
Ann C. Horan - Summit NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C12N 9/10
C12N 15/74
C12N 15/64
C12N 1/20
C12N 1/00
C12P 21/06
C07H 21/04

US Classification:

435193, 435 691, 435 914, 4352523, 43525411, 435471, 536 231, 536 232

Abstract:

This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into. Thus, the invention further provides methods for introducing heterologous genes into an actinomycete chromosome using this particular vector.

US Patent:

7790411, Sep 7, 2010

Filed:

Apr 25, 2007

Appl. No.:

11/739945

Inventors:

Thomas J. Hosted - Summit NJ, US
Tim X. Wang - Roselle Park NJ, US
Ann C. Horan - Summit NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C12P 21/06
C12P 19/34
C12N 15/00
C12N 1/20
C12N 15/07
C07H 21/02
C07H 21/04

US Classification:

435 691, 435 911, 435183, 4352521, 4353201, 435471, 536 231, 536 232, 536 237

Abstract:

This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into. Thus, the invention further provides methods for introducing heterologous genes into an actinomycete chromosome using this particular vector.

US Patent:

7947480, May 24, 2011

Filed:

Sep 3, 2010

Appl. No.:

12/875342

Inventors:

Thomas J. Hosted - Summit NJ, US
Tim X. Wang - Roselle Park NJ, US
Ann C. Horan - Summit NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C12N 9/02
C12N 9/00
C12N 15/00
C12N 1/20
C12P 21/06
C12P 19/34
A61K 39/395
C07H 21/02
C07H 21/04

US Classification:

435189, 435183, 435 691, 435 911, 4353201, 4352523, 4241301, 4241461, 536 231, 536 232

Abstract:

This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into. Thus, the invention further provides methods for introducing heterologous genes into an actinomycete chromosome using this particular vector.

US Patent:

20110269216, Nov 3, 2011

Filed:

May 2, 2011

Appl. No.:

13/098645

Inventors:

Thomas J. Hosted - Summit NJ, US
Tim X. Wang - Roselle Park NJ, US
Ann C. Horan - Summit NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C12N 15/63
C07H 21/04
C12N 1/21

US Classification:

43525233, 4353201, 4352523, 536 231, 536 234, 536 232

Abstract:

This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Thus, the invention further provides methods for introducing heterologous genes into an actinomycete chromosome using this particular vector.

US Patent:

58376917, Nov 17, 1998

Filed:

Aug 12, 1991

Appl. No.:

7/747456

Inventors:

Vinod R. Hegde - Parsippany NJ
Ann C. Horan - Summit NJ
Mahesh G. Patel - Verona NJ

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 3171
C07H 1708

US Classification:

514 29

Abstract:

A novel macrolactam monosaccharide isolated from an antimicrobial complex 517 produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Actinomadura vulgaris subsp. vulgaris ATCC 53748.